Lymphoid Malignancies at Wilmot
Lymphoma and Chronic Lymphocytic Leukemia
If you or someone in your family is diagnosed with lymphoma or chronic lymphocytic leukemia (CLL), the Wilmot Cancer Institute is prepared to help. Our multi-disciplinary team of experts is committed to providing you the highest level of care. The Wilmot Cancer Institute is home to one of the best lymphoma and CLL programs in the country. Our physicians are continuously developing new treatment combinations for patients with all types of lymphoma and CLL, and at various stages of disease. Through our clinical trials program we are improving upon the standard of care, and creating novel approaches for patients who don’t benefit from conventional treatment. As leaders in the field, our experienced physicians oversee numerous clinical studies aimed to identify the most effective new drug combinations for lymphoma and CLL, while incorporating innovations in precision diagnosis and treatment.
As an internationally recognized center for Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and CLL, we are extensively involved in collaborative research with physician scientists here at The University of Rochester, as well as with research groups across the country, and globally. Our work has contributed to fundamental changes in the current understanding of lymphoma biology, and has significantly impacted treatment options for patients with all types of lymphoma and CLL. Our multi-disciplinary team includes experts from lymphoma and CLL, benign hematology, pathology, radiation oncology, stem-cell transplant, and dermatology. We collaborate to provide the highest quality care for over 300 new lymphoma and CLL patients, and many more outpatients, per year. Each patient benefits from a treatment plan developed by our disease team together, so you benefit from the joint expertise of the group. As the largest lymphoma and CLL program in upstate New York, patients travel to Rochester from across the country for the expertise in diagnosis, treatment, and clinical studies that are only available at our institution.
Why The Lymphoma/CLL Program at Wilmot?
We are an internationally recognized center for excellence in lymphoma and CLL, and are home to a team of physicians who are experts in the field
Wilmot is the only medical center in the region with a unique specialty clinic for the treatment of CLL
We provide access to more clinical trials for lymphoma and CLL than any other center in the region, offering innovative treatments including targeted biological drugs, radiation, and immunotherapy. Wilmot houses the region’s only center for stem cell transplants (both autologous and allogeneic).
Lymphoma/CLL Clinical Research at Wilmot
The Wilmot Cancer Institute at the University of Rochester Medical Center is considered one of the world’s leading lymphoma and CLL research centers. Our clinical and basic science research programs continuously seeks to further our understanding of how lymphoma and CLL specifically develop and progress, what makes them different from other cancers, and applies this knowledge to new treatment strategies.
Clinical trials offer new ways to treat lymphoma by testing different combination of drugs, and improving existing therapies to make them more effective, safer and longer lasting. Our lymphoma and CLL program has multiple active and ongoing clinical trials for patients with lymphoma and CLL. Our research allows us to offer patients more treatment options before they become widely available and in particular may provide hope for patients with cases of lymphoma that are particularly resistant to traditional therapies.
Wilmot recently inaugurated the CLL Program, led by Dr. Clive Zent. This specialized program for CLL research and treatment offers a full range of diagnostic options to accurately stage CLL, determine disease prognosis, and plan the best treatment, on an individual basis.
Our basic science research program permits discoveries made in the laboratory to directly impact patients in the clinic (known as translational medicine). These collaborations lead us closer toward individualized treatments based on the specific biology of a person’s disease and show great promise for changing the way lymphoma is understood and treated.
The Wilmot Cancer Institute’s team approach to lymphoma and CLL is complemented by our extensive research program. We are committed to giving you and your loved one the highest level of care.